Healthcare

XERS.US – Xeris Pharmaceuticals Inc

2025-01-07T17:17:27+00:00Categories: Biotechnology|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Address: 180 North LaSalle Street, Chicago, IL, United States, 60601

XENE.US – Xenon Pharmaceuticals Inc

2025-01-07T17:17:24+00:00Categories: Biotechnology|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Address: 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8

XCUR.US – Exicure Inc

2025-01-07T17:17:13+00:00Categories: Biotechnology|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. Address: 2430 North Halsted Street, Chicago, IL, United States, 60614

XBIT.US – XBiotech Inc

2025-01-07T17:17:01+00:00Categories: Biotechnology|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Address: 5217 Winnebago Lane, Austin, TX, United States, 78744

XBIO.US – Xenetic Biosciences Inc

2025-01-07T17:16:58+00:00Categories: Biotechnology|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Address: 945 Concord Street, Framingham, MA, United States, 01701

XAIR.US – Beyond Air Inc

2025-01-07T17:16:54+00:00Categories: Medical Devices|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York. Address: 900 Stewart Avenue, Garden City, NY, United States, 11530

WVE.US – Wave Life Sciences Ltd

2025-01-07T17:16:16+00:00Categories: Biotechnology|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. Address: Marina One East Tower, Singapore, Singapore, 018936

WST.US – West Pharmaceutical Services Inc

2025-01-07T17:15:11+00:00Categories: Medical Instruments & Supplies|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania. Address: 530 Herman O. West Drive, Exton, PA, United States, 19341-1147

WRBY.US – Warby Parker Inc

2025-01-07T17:14:14+00:00Categories: Medical Instruments & Supplies|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. Address: 233 Spring Street, New York, NY, United States, 10013

WORX.US – Scworx Corp

2025-01-07T17:13:43+00:00Categories: Health Information Services|Tags: Healthcare, USA|

Name:
Trailing PE:
Forward PE:
Price Sales TTM:
Price Book MRQ:
Enterprise Value Revenue:
Enterprise Value Ebitda:

SCWorx Corp. engages in the development and marketing of health care information technology solutions and related services to improve healthcare processes and information flow within hospitals and other healthcare facilities in the United States. It offers software solutions, including virtualized item master file repair, expansion, and automation; electronic medical record management; charge description master management; contract management; request for proposal automation; integration of acquired business; rebate management; big data analytics modeling; data integration and warehousing; and ScanWorx. The company also provides data content and services related to repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. It sells its solutions and services to the hospitals and health systems through direct sales force, and distribution and reseller partnerships. SCWorx Corp. is based in Tampa, Florida. Address: 100 South Ashley Drive, Tampa, FL, United States, 33602